Shares of IXICO plc (LON:IXI – Get Free Report) dropped 9.9% during mid-day trading on Friday . The company traded as low as GBX 8 and last traded at GBX 8. Approximately 242,177 shares changed hands during trading, an increase of 114% from the average daily volume of 113,365 shares. The stock had previously closed at GBX 8.88.
IXICO Stock Performance
The company has a 50-day moving average price of GBX 10.98 and a two-hundred day moving average price of GBX 11.51. The company has a market capitalization of £6.91 million, a PE ratio of -4.03, a PEG ratio of -0.38 and a beta of 0.86. The company has a quick ratio of 4.90, a current ratio of 2.85 and a debt-to-equity ratio of 3.32.
IXICO (LON:IXI – Get Free Report) last posted its earnings results on Tuesday, December 9th. The company reported GBX (1.85) earnings per share for the quarter. IXICO had a negative net margin of 31.10% and a negative return on equity of 19.14%. Analysts predict that IXICO plc will post -289.3584879 EPS for the current fiscal year.
About IXICO
IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring.
By unlocking valuable insights into drug safety and efficacy, IXICO has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) managing and analysing neurological clinical trials.
Featured Articles
- Five stocks we like better than IXICO
- 3 Signs You May Want to Switch Financial Advisors
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- From Quiet Compounder to 2026 Breakout? BSEM
- Congress Is Building a System to Control How You Spend Your Money
Receive News & Ratings for IXICO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IXICO and related companies with MarketBeat.com's FREE daily email newsletter.
